The case for inhaled pharmaceuticals
Delivering drugs directly to their site of action in the lungs often results in fewer systemic side-effects and generally requires lower doses than other drug delivery methods.
The respiratory market
Asthma and COPD make up the third-fastest growing marketplace for therapeutic treatments, with the total market estimated to be worth more than $21 billion in the US alone. The increase in fixed-dose combinations, and ongoing advances in effective therapies mean this figure will continue to grow. Our products for asthma and COPD target over half of this ever-expanding global market.
Vectura's key to success
Vectura's focused application of technology, know-how and expertise has demonstrated that the potential for new inhaled pharmaceuticals with real therapeutic and commercial value can be realised. The selection of drug candidates and market opportunities that can benefit from advances in inhalation technology, together with the ability to progress development swiftly and to partner where appropriate with major pharmaceutical companies for optimal value exploitation, are the prime drivers for the Company's success.
For more information please go to Investor Profile
More